In the final analysis of JAVELIN Renal 101, avelumab + axitinib maintained superior PFS and nearly doubled ORR versus sunitinib; overall survival (OS) favoured the combination but did not reach statistical significance (overall population: median 44.8 vs 38.9 months, HR 0.88).
← all excerpts
Late cutaneous metastasis of clear-cell renal cell carcinoma to the lower eyelid five years after radical nephrectomy: A case report.
1
—
—